Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vexo-AAV6-iCasp9
- Development stage
- Unknown
- Lead developer
- Indian Institute of Technology Kanpur Laurus Center for Gene Therapy
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
Vexo-AAV6-iCasp9 is a gene therapy product consisting of an exosome-associated adeno-associated virus serotype 6 (AAV6) vector carrying an inducible caspase 9 (iCasp9) suicide gene. The iCasp9 transgene is activated in the presence of the dimerizer drug AP20187, triggering apoptosis selectively in transduced cells. Vexo-AAV6-iCasp9 has demonstrated enhanced cytotoxicity and tumor regression in preclinical models of hepatocellular carcinoma and breast cancer. The exosome-based (vexosome) delivery adds functional efficiency and ease of isolation for clinical use. This approach is designed for intratumoral gene therapy targeting solid malignancies through induction of programmed cell death[1][2][3].
- Brand names
- Vexo-AAV6-iCasp9Vexo-AAV-6-iCasp9Vexo-AAV 6-iCasp9
- Other names
- Vexo-AAV6-iCasp9Vexo-AAV-6-iCasp9Vexo-AAV 6-iCasp9AAV6-iCasp9 vexosomeAAV-6-iCasp9 vexosomeAAV 6-iCasp9 vexosome
02
Targets
iCasp9 (Inducible caspase-9)
Beyond the preview
Go deeper on Vexo-AAV6-iCasp9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vexo-AAV6-iCasp9.